VED

Ensurge starts manufacturing scale-up and commercialization of the world’s first high energy density rechargeable solid-state microbatteries

Retrieved on: 
Monday, May 22, 2023

In addition to this progress, Ensurge has started producing sample volumes of high capacity multi-layer solid-state lithium microbatteries using its innovative and unique architecture based on a 10-micron stainless steel substrate.

Key Points: 
  • In addition to this progress, Ensurge has started producing sample volumes of high capacity multi-layer solid-state lithium microbatteries using its innovative and unique architecture based on a 10-micron stainless steel substrate.
  • Achieving these industry-first milestones is a major step toward bringing Ensurge's solid-state microbattery products into volume production.
  • “These two milestones are extremely significant for Ensurge as it prepares to scale production for these market-changing solid-state lithium microbatteries.
  • Our batteries will revolutionize the way next generation products are designed to enable enhanced capabilities and performance,” said Mark Newman, Ensurge Chief Executive Officer.

Ensurge Shares Technical Data Establishing that Solid-State Lithium Microbattery Performance Will Eliminate Barriers to Wearable and Hearable Innovation

Retrieved on: 
Monday, March 6, 2023

Li-ion microbattery limitations have prevented product manufacturers from meeting growing market demand for new features and enhanced charging capabilities.

Key Points: 
  • Li-ion microbattery limitations have prevented product manufacturers from meeting growing market demand for new features and enhanced charging capabilities.
  • Ensurge provided TechBlick conference attendees with data it had gathered from tests of its microbattery’s core cells.
  • Kamath shared data that showed that the Ensurge microbattery core cells have achieved hundreds of cycles in the last few months.
  • “These performance milestones offer further validation that the Ensurge solid-state lithium microbattery is poised to replace Li-ion alternatives in wearables and hearables while giving these products transformative new features and capabilities,” Kamath said.

Vivian Health Expands Leadership Team with Strategic Executive Appointments

Retrieved on: 
Monday, March 6, 2023

Vivian Health, the leading national healthcare jobs marketplace, today announced key appointments to expand its executive leadership team as the company positions itself to thrive in the year ahead.

Key Points: 
  • Vivian Health, the leading national healthcare jobs marketplace, today announced key appointments to expand its executive leadership team as the company positions itself to thrive in the year ahead.
  • These include the appointment of Adam Greenberg to Chief Financial Officer and Ved Sinha to Chief Product Officer.
  • “We are delighted to welcome Adam Greenberg and Ved Sinha to Vivian Health,” said Parth Bhakta, Chief Executive Officer and co-founder of Vivian Health.
  • Mr. Sinha joins Vivian from Robert Half, a leading talent solutions company, where he was Vice President of Product Management.

Purple Quarter Appoints Ex-Alibaba/Lazada, Ved Prakash, as Regional CEO

Retrieved on: 
Monday, January 16, 2023

SINGAPORE, Jan. 16, 2023 /PRNewswire/ -- Global Bespoke CTO Search Firm, Purple Quarter today announced Ved Prakash as the Regional CEO to oversee its operations in the newly expanded APAC, Europe and US markets. The appointment is a strategic move to bolster Purple Quarter's 2023-24 global initiatives.

Key Points: 
  • SINGAPORE, Jan. 16, 2023 /PRNewswire/ -- Global Bespoke CTO Search Firm, Purple Quarter today announced Ved Prakash as the Regional CEO to oversee its operations in the newly expanded APAC, Europe and US markets.
  • Roopa Kumar , Group CEO & Founder shared on the appointment, "Purple Quarter's vision is to empower businesses and global leaders to accelerate their growth journey.
  • An industry veteran with 18+ years of experience, Ved has had remarkable associations with Alibaba, Lazada, Google, Flipkart, Cisco and GE.
  • "I wish to thank Roopa for this incredible opportunity," shared Ved Prakash , "Purple Quarter's niche offerings hold immense potential globally.

Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

Retrieved on: 
Monday, January 9, 2023

NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.

Key Points: 
  • NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.
  • “Our commitment to patients is the cornerstone of our mission, and we are proud to have secured our first FDA approval.
  • We are eager to report the topline results from our ongoing Phase 2a trial of ACER-801 in moderate to severe VMS in post-menopausal women in Q1 of 2023.
  • These trial results will provide important insight into ACER-801’s therapeutic potential in induced VMS (iVMS).

Acer Therapeutics to Participate in August and September 2022 Investor Conferences

Retrieved on: 
Tuesday, August 23, 2022

Date and Time: On-demand corporate presentation available beginning at 7 am ET, September 12, 2022

Key Points: 
  • Date and Time: On-demand corporate presentation available beginning at 7 am ET, September 12, 2022
    Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Acers pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19.
  • For more information, visit www.acertx.com .

DGAP-News: Enapter and VINCI Energies in Germany sign cooperation agreement

Retrieved on: 
Friday, April 1, 2022

Enapter GmbH, a wholly owned subsidiary of the listed Enapter AG (ISIN:DE000A255G02), has entered into a cooperation agreement with the system integrator VINCI Energies Deutschland Industry & Infrastructure GmbH (VINCI Energies for short).

Key Points: 
  • Enapter GmbH, a wholly owned subsidiary of the listed Enapter AG (ISIN:DE000A255G02), has entered into a cooperation agreement with the system integrator VINCI Energies Deutschland Industry & Infrastructure GmbH (VINCI Energies for short).
  • Under this collaboration, Enapter will provide AEM-Multicore equipment capable of producing approximately 450 kilograms of green hydrogen per day.
  • The decision to cooperate between Enapter and VINCI Energies was preceded by the two partners getting to know each other through Startup Connect.
  • "We are very pleased to be working with such a renowned and experienced partner in plant engineering for industry and energy infrastructure as VINCI Energies in Germany.

Global Erectile Dysfunction Market Outlook and Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021

The "Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global erectile dysfunction market is expected to observe a negative growth during the forecast period on account of the decline in revenue from the ED therapeutics segment.
  • The global ED drugs market is observed to be oligopoly in nature, wherein only few sellers occupy dominant the market share.
  • The following factors are likely to contribute to the growth of the erectile dysfunction market during the forecast period:

InventHelp Inventor Develops Less Invasive Treatment Option for Erectile Dysfunction (PIT-985)

Retrieved on: 
Tuesday, April 7, 2020

PITTSBURGH, April 7, 2020 /PRNewswire/ -- "I'm a doctor and I wanted to create a less invasive treatment option for patients with erectile dysfunction," said an inventor, from Cumberland, Md., "so I invented the MALE HELPER."

Key Points: 
  • PITTSBURGH, April 7, 2020 /PRNewswire/ -- "I'm a doctor and I wanted to create a less invasive treatment option for patients with erectile dysfunction," said an inventor, from Cumberland, Md., "so I invented the MALE HELPER."
  • The invention provides an improved way to help treat erectile dysfunction.
  • As a result, it could enhance personal comfort and it could provide added peace of mind.
  • The invention features an effective design that is easy to apply and use so it is ideal for men with erectile dysfunction.

Edmedcare Introduces Elite Medication for Erectile Dysfunction and a Fast Discreet Online Doctor Consultation

Retrieved on: 
Wednesday, March 4, 2020

NEW YORK, March 4, 2020 /PRNewswire/ -- Edmedcare.com is offering free, fast, online and discreet consultation for erectile dysfunction with a licensed MD from the privacy of the consumer's home.

Key Points: 
  • NEW YORK, March 4, 2020 /PRNewswire/ -- Edmedcare.com is offering free, fast, online and discreet consultation for erectile dysfunction with a licensed MD from the privacy of the consumer's home.
  • Once approved, a licensed pharmacy will deliver specially formulated ED medication containing NZT-V and NZT-C to the customer's doorstep.
  • The ED medication addresses problems related to Erectile Dysfunction also known as "ED".
  • Edmedcare's online system is HIPAA compliant and starts with a free, online consultation.